Name | Xylometazoline hydrochloride |
Description | Xylometazoline hydrochloride (Xylometazoline HCl) is an α-adrenoceptor agonist usually used as nasal decongestant. |
In vitro | Xylometazoline is an α-adrenoceptor agonist commonly used as nasal decongestant, exhibits highest potency at α2B-adrenoceptor subtype with EC50 of 99 μM. Xylometazoline binds at adrenoceptor subtypeα1A, α1B, α1D, α2A, α2B, α2C with IC50 of 0.08, 0.56, 0.45, 0.98, 1.8, 0.22 μM, repectively. [1] |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 16 mg/mL (56.97 mM), Sonication is recommended. Ethanol : 52 mg/mL (185.2 mM) H2O : 51 mg/mL (181.6 mM)
|
Keywords | Adrenergic Receptor | increase nasal airflow | constrict nasal blood vessels | nose stuffiness | Inhibitor | Xylometazoline hydrochloride | Xylometazoline Hydrochloride | Beta Receptor | inhibit | Xylometazoline | runny nose |
Inhibitors Related | Olanzapine | Mirtazapine | Octopamine hydrochloride | Gemfibrozil | Dexmedetomidine hydrochloride | Phenylephrine hydrochloride | Isoprenaline hydrochloride | Amitriptyline hydrochloride | Trazodone hydrochloride | Mianserin hydrochloride |
Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Adrenergic Receptor-Targeted Compound Library | GPCR Compound Library | Anti-Cancer Drug Library |